In May 2015, I attended a conference for lung cancer patients in Washington DC. There were close to 200 patients in attendance, but only five with my specific diagnosis: ROS1+ Adenocarcinoma. We saw what a minority we were within the lung cancer community and knew it would be up to us to find and create our own âtribe.â The five of us met up in the hotel bar to discuss how we might find other ROS1+ patients to share knowledge and improve our survival odds.